Want to create an interactive transcript for this episode?
Podcast: Surfing the MASH Tsunami
Episode: S5 - E12.2 - MASH Drug Development: Improving Efficacy Endpoints
Description: In this conversation, the panel discusses challenges in MASH Drug Development that are centered around efficacy endpoints and NAS scoring.This conversation starts with Will Alazawi suggesting that the MASH clinical trial field suffers from the previous experience with Hepatitis C, where medications became capable of eradicating disease in a fairly linear fashion. He suggests that MASH trials undervalue the value of simply preventing progression, which leads Sven Francque to note that preventing progression to cirrhosis is now accepted by regulators as an endpoint. Roger Green refers to last week's episode (S5 – E11), in which Mic...